US

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Republic of Korea *

img-antibody-drug-conjugate-services-white-paper1920x640

Whitepaper

Preclinical screening platforms for antibody-drug conjugate therapeutics

Antibody Drug Conjugates (ADCs) are a hot topic in drug discovery as one of the most rapidly expanding oncology therapeutic categories.

Learn more about ADCs and the role that screening can play to help advance the discovery process for ADC therapeutic candidates in this white paper.

You will learn about:

An overview of ADCs, why they're important in oncology drug discovery and key considerations in ADC design
The role of cell panel screening for ADC-based combination therapies
The importance of screening genetic drives and mechanisms of action and resistance
Optimization of ADC structure using immune cell-based screening

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

Have a sales representative contact me

First Name

Last Name

Country

Email Address

Company

Zip / Postal Code

Business Phone

Role

Products and Services of Interest

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Preclinical screening platforms for antibody-drug conjugate therapeutics

Download Whitepaper